DopAmide

DopAmide
Clinical data
Other names	L-DopAmide; 3-Hydroxytyrosinamide
Drug class	Monoamine precursor; Dopamine receptor agonist
Identifiers
	IUPAC name 2-amino-3-(3,4-dihydroxyphenyl)propanamide;
CAS Number	73148-96-6;
PubChem CID	424633;
ChemSpider	375743;
Chemical and physical data
Formula	C9H12N2O3
Molar mass	196.206 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC(=C(C=C1CC(C(=O)N)N)O)O;
	InChI InChI=1S/C9H12N2O3/c10-6(9(11)14)3-5-1-2-7(12)8(13)4-5/h1-2,4,6,12-13H,3,10H2,(H2,11,14); Key:DXOJUCNAHCVBRU-UHFFFAOYSA-N;

DopAmide, or L-DopAmide, is a synthetic levodopa (L-DOPA) analogue that can serve as a levodopa and dopamine prodrug and is of potential interest in the treatment of Parkinson's disease.^[1]^[2]^[3] DopAmide has an amide rather than the carboxyl group of L-DOPA,^[2]^[3] which imparts greater water solubility.^[1]^[2]^[3] The amide is hydrolyzed back to the acid by aminopeptidase enzymes.^[1]^[2]^[3]

References

^ ^a ^b ^c Kang T, Miao Z, Liu S, Ke B (2021). "Prodrug Strategies in the CNS Drugs: Small Modification Makes Big Improvements". Current Topics in Medicinal Chemistry. 21 (24): 2157–2169. doi:10.2174/1568026621666210727163827. PMID 34315372.
^ ^a ^b ^c ^d Urso D, Chaudhuri KR, Qamar MA, Jenner P (November 2020). "Improving the Delivery of Levodopa in Parkinson's Disease: A Review of Approved and Emerging Therapies". CNS Drugs. 34 (11): 1149–1163. doi:10.1007/s40263-020-00769-7. PMID 33146817.
^ ^a ^b ^c ^d Atlas D (June 2016). "DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons". CNS Neuroscience & Therapeutics. 22 (6): 461–467. doi:10.1111/cns.12518. PMC 6492885. PMID 26861609.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.